Open Access<p>Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study</p>
Author(s) -
Qian Geng,
Hua Shen,
WenYuan Zhu,
Yingzhi Lu,
Mengjie Wang,
Hua Jiang,
Dongqing Li
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s277532
Subject(s) - apatinib , medicine , clinical endpoint , response evaluation criteria in solid tumors , oncology , adverse effect , refractory (planetary science) , lung cancer , gastroenterology , progressive disease , chemotherapy , surgery , clinical trial , astrobiology , physics
Lung squamous-cell carcinoma (SqCC) is the second most common histology in non-small-cell lung carcinomas (NSCLCs). The treatment options for advanced lung SqCC are still an unmet medical need. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is beneficial in the therapy of advanced NSCLC patients. This study aimed to preliminarily assess the efficacy and safety of low-dosage apatinib in patients with advanced lung SqCC.